Company intelligence / Profile preview

ViroCarb Inc.

Toronto, Ontario, Canadavirocarb.com ↗

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

ViroCarb has developed a new series of small molecule inhibitors that impair viral RNA processing to block replication of multiple important pathogenic viruses. The company’s approach aims for broad-spectrum antiviral efficacy via a single host-directed mechanism. Clinical results are not yet available; programs are in preclinical development.

Therapeutic areas: Infectious Diseases
Modalities: small molecules
Industry: Biotech

Drug pipeline

1 asset

GPS-543

Preclinical

Partnerships

Academic collaborations with University of Toronto, University of British Columbia, Université de Sherbrooke

Beyond the preview

Go deeper on ViroCarb Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViroCarb Inc..

Explore the full profile